← board
QGEN
distress 0/10 · well-funded / low risk$41.23+2%today-26% from 52w high
Revenue
$2090M
Liquidity
$1099M
Runway
—
Shares 1y
0%
Price & events
-23.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.6%
1D
-0.7%
1W
+11.8%
1M
+9.6%
3M
-25.2%
6M
-17.5%
1Y
+0.9%
2Y
-19.6%
5Y
-21.6%
All
Overview
- Market Cap
- $8.94B
- Enterprise Value
- $9.76B
- Volume
- 276.98K
- 52 Week Range
- $32.63 – $55.66
- Total Shares
- 216.92M
- Float Shares
- 204.78M
- Short %
- 3.63%
- % Held by Insiders
- 0.47%
- % Held by Institutions
- 81.91%
- RVOL
- 0.10x
- Beta
- 0.64
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $44 (+7% upside) · 14 analysts
- 2026-06-23Morgan StanleyEqual-Weight → Overweight
- 2026-05-18StifelHold
- 2026-05-07TD CowenHold
- 2026-04-29CitigroupNeutral
- 2026-04-29BairdNeutral → Outperform
- 2026-04-29JP MorganOverweight
Competitors
- none identified
Recent news
- 2026-07-23Hsbc Holdings PLC Invests $12.92 Million in Qiagen N.V. $QGEN - MarketBeat
- 2026-07-23Qiagen stock steadies as investors weigh recent earnings and molecular diagnostics growth - Ad-hoc-news.de
- 2026-07-22PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
- 2026-07-21Qiagen stock holds firm as diagnostics demand supports revenue growth - Ad-hoc-news.de
- 2026-07-21Qiagen stock trades steady as recent results highlight margin resilience - Ad-hoc-news.de
- 2026-07-21Qiagen stock rises on recent results and market data - Ad-hoc-news.de
- 2026-07-21Baader Bank Aktiengesellschaft Buys New Stake in Qiagen N.V. $QGEN - MarketBeat
- 2026-07-20Qiagen N.V. (QGEN) Stock Analysis: Evaluating The 7.09% Upside Potential For Investors - DirectorsTalk Interviews
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.